Kezar Life Sciences (NASDAQ:KZR) Issues Earnings Results, Beats Estimates By $0.20 EPS

Kezar Life Sciences (NASDAQ:KZR) announced its quarterly earnings data on Monday. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.20, Zacks reports.

Kezar Life Sciences Stock Down 1.0%

KZR stock opened at $7.29 on Tuesday. The company has a market capitalization of $53.87 million, a price-to-earnings ratio of -0.95 and a beta of 0.40. Kezar Life Sciences has a 12 month low of $3.53 and a 12 month high of $7.55. The firm has a 50 day moving average of $7.12 and a two-hundred day moving average of $6.56.

Institutional Trading of Kezar Life Sciences

Large investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. bought a new stake in Kezar Life Sciences in the third quarter worth approximately $51,000. Torno Capital LLC bought a new stake in Kezar Life Sciences in the fourth quarter worth approximately $126,000. Woodline Partners LP bought a new stake in Kezar Life Sciences in the first quarter worth approximately $125,000. Dimensional Fund Advisors LP grew its position in Kezar Life Sciences by 14.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock worth $167,000 after acquiring an additional 3,312 shares in the last quarter. Finally, State Street Corp grew its position in Kezar Life Sciences by 28.4% in the fourth quarter. State Street Corp now owns 27,093 shares of the company’s stock worth $170,000 after acquiring an additional 6,000 shares in the last quarter. 67.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kezar Life Sciences in a research report on Friday. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $6.00.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.